A Phase II Dose-Finding Study of weekly pemetrexed in combination with Radiotherapy in locally advanced pancreatic adenocarcinoma - ND

ISTITUTO ONCOLOGICO ROMAGNOLO0 个研究点开始时间: 2007年11月9日最近更新: 2012年3月19日

试验速览

暂无简介。

•·Patients must have histologically or cytologically confirmed locally advanced adenocarcinoma of the exocrine pancreas not amenable to surgical resection because of vascular invasion or extensive lymph-node involvement.
•·Patients must have measurable disease, according to RECIST criteria.
•·Patients must be treatment-naïve
•·Age >=18 years.
•·Life expectancy greater than three months
•·ECOG performance status <=2
•·Patients must adequate organ and marrow function
•·Ability to understand and the willingness to sign a written informed consent document.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•·Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
•·Patients with distant metastases
•·Untreated renal failure or hyperbilirubinemia
•·Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
•·Pregnant or nursing patients because of the teratogenic effects of this combination.
•·Cancer survivors can be included only if they have not been treated with abdominal radiotherapy.

发起方